The generation of stable human T-cell hybridomas which constitutively produce interleukin-2 and chemotactic factor. 1985

K A Foon, and J L Rossio, and R W Schroff, and S M Wahl, and F W Ruscetti, and P G Abrams, and H C Rager, and S F Pickeral, and I J Fidler

We report the successful generation of human T-cell hybridomas that constitutively secrete lymphokines. An acute lymphoblastic leukemia T-cell line, CCRF-H-SB2, free of reverse transcriptase and mycoplasma, was sensitized to hypoxanthine, aminopterin, and thymidine (HAT) by selecting out a mutant deficient in hypoxanthine guanine phosphoribosyl transferase (HGPRT) in 8-azaguanine. Peripheral blood T lymphocytes from normal donors were incubated in vitro with 10 micrograms/ml of concanavalin A for 48 h and subsequently fused with the CCRF-H-SB2 HAT-sensitive cell line. Following 5 weeks in culture, 38 of 440 wells (8.6%) demonstrated hybridoma growth. Supernatants of these cultures were screened for interleukin-2 (IL-2), chemotactic factor, interferon, migration inhibition factor, and macrophage-activating factor activities. Twelve (of 38) hybrids exhibited IL-2 activity, and eight of these were successfully cloned. The highest secreting clone was demonstrated to have mRNA to IL-2 while the parent CCRF-H-SB2 had no detectable mRNA to IL-2. Three hybrid cultures produced chemotactic factor; one was successfully cloned and grown in serum-free medium, where it continued to constitutively produce chemotactic factor as well as IL-2 activity. The chemotactic factor was determined to have the same molecular weight (12,500 daltons) as leukocyte-derived chemotactic factor. Constitutive IL-2 production remained stable for over 12 months. None of the hybridomas tested produced detectable levels of gamma interferon, migration inhibition factor, or macrophage activation factor. Because these T-cell hybridomas produce lymphokines constitutively and this phenotype is stable, they can be an important source of highly purified human lymphokines for clinical and laboratory investigations.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002630 Chemotactic Factors Chemical substances that attract or repel cells. The concept denotes especially those factors released as a result of tissue injury, microbial invasion, or immunologic activity, that attract LEUKOCYTES; MACROPHAGES; or other cells to the site of infection or insult. Chemoattractant,Chemotactic Factor,Chemotaxin,Chemotaxins,Cytotaxinogens,Cytotaxins,Macrophage Chemotactic Factor,Chemoattractants,Chemotactic Factors, Macrophage,Macrophage Chemotactic Factors,Chemotactic Factor, Macrophage,Factor, Chemotactic,Factor, Macrophage Chemotactic
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K A Foon, and J L Rossio, and R W Schroff, and S M Wahl, and F W Ruscetti, and P G Abrams, and H C Rager, and S F Pickeral, and I J Fidler
January 1985, Hybridoma,
K A Foon, and J L Rossio, and R W Schroff, and S M Wahl, and F W Ruscetti, and P G Abrams, and H C Rager, and S F Pickeral, and I J Fidler
November 1982, Nature,
K A Foon, and J L Rossio, and R W Schroff, and S M Wahl, and F W Ruscetti, and P G Abrams, and H C Rager, and S F Pickeral, and I J Fidler
August 1985, Journal of immunological methods,
K A Foon, and J L Rossio, and R W Schroff, and S M Wahl, and F W Ruscetti, and P G Abrams, and H C Rager, and S F Pickeral, and I J Fidler
November 1985, Journal of immunology (Baltimore, Md. : 1950),
K A Foon, and J L Rossio, and R W Schroff, and S M Wahl, and F W Ruscetti, and P G Abrams, and H C Rager, and S F Pickeral, and I J Fidler
May 1992, Molecular biology reports,
K A Foon, and J L Rossio, and R W Schroff, and S M Wahl, and F W Ruscetti, and P G Abrams, and H C Rager, and S F Pickeral, and I J Fidler
April 1989, Hybridoma,
K A Foon, and J L Rossio, and R W Schroff, and S M Wahl, and F W Ruscetti, and P G Abrams, and H C Rager, and S F Pickeral, and I J Fidler
February 1985, Journal of immunological methods,
K A Foon, and J L Rossio, and R W Schroff, and S M Wahl, and F W Ruscetti, and P G Abrams, and H C Rager, and S F Pickeral, and I J Fidler
August 1985, European journal of immunology,
K A Foon, and J L Rossio, and R W Schroff, and S M Wahl, and F W Ruscetti, and P G Abrams, and H C Rager, and S F Pickeral, and I J Fidler
August 1985, European journal of immunology,
K A Foon, and J L Rossio, and R W Schroff, and S M Wahl, and F W Ruscetti, and P G Abrams, and H C Rager, and S F Pickeral, and I J Fidler
June 1986, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!